PATENT CLAIM ANALYSIS

Application Number: 16387255
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["514", "210200"]

Abstract:
Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

Claim (Index 4):
The method of  claim 1 , wherein the compound is in the form of a tablet, pill, sachet, or capsule of hard or soft gelatin.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 100.0
- Lexical Diversity: 1.325
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16387318', '15673084', '15018814', '15401894', '14701304']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8033731593084954
- 35 USC 102 Novelty (BERT): 0.6033718861738229
- Combined Prediction Score: 0.7833730319950282
- Mean Citation Score: 369.08402
- Max Citation Score: 510.0256
- Similarity Product: 506.7650288925171

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test